Document Detail


Tardive dyskinesia and atypical antipsychotic drugs.
MedLine Citation:
PMID:  10190226     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.
Authors:
D E Casey
Related Documents :
18609426 - Increased motor activity in cycloid psychosis compared to schizophrenia.
10866026 - Prenatal illness and subtypes of schizophrenia: the winter pregnancy phenomenon.
8353696 - A pilot study of schizophrenia-like psychosis in epilepsy using single-photon emission ...
1912106 - Plasma phenylethylamine in schizophrenic patients.
8339126 - Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus.
23081756 - Disturbed vestibular-neck interaction in cerebellar disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Schizophrenia research     Volume:  35 Suppl     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-07-21     Completed Date:  1999-07-21     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  S61-6     Citation Subset:  IM    
Affiliation:
Mental Health Division, Veterans Affairs Medical Center, Portland, OR 97207, USA. daniel.casey@med.VA.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Aged
Antipsychotic Agents / adverse effects*
Basal Ganglia Diseases / chemically induced
Benzodiazepines
Clozapine / adverse effects
Dyskinesia, Drug-Induced / diagnosis*
Female
Humans
Male
Middle Aged
Pirenzepine / adverse effects,  analogs & derivatives
Risperidone / adverse effects
Schizophrenia / drug therapy
Sex Factors
Grant Support
ID/Acronym/Agency:
MH36657/MH/NIMH NIH HHS; RP00163//PHS HHS
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 28797-61-7/Pirenzepine; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cognitive improvement in schizophrenia with novel antipsychotic medications.
Next Document:  Prolactin and antipsychotic medications: mechanism of action.